Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Incorporated (NYSE: DGX) is a medical laboratories company focused on diagnostic testing and diagnostic information services, and its news flow reflects its role across the healthcare ecosystem. The company regularly issues updates on its financial reporting schedule, including announcements about quarterly and full-year results and related conference calls, which are of interest to investors tracking DGX stock and performance trends.
News about Quest Diagnostics also covers participation in major healthcare and investor conferences. For example, the company has announced presentations at events such as the J.P. Morgan Healthcare Conference and Citi’s Global Healthcare Conference, where its leadership discusses strategy, performance and market developments. These appearances provide insight into how the company views its position in the diagnostic testing and information services market.
Quest Diagnostics’ news includes information on collaborations and joint ventures that expand access to laboratory services. Announcements have highlighted a laboratory services joint venture with Corewell Health in Michigan, as well as the ongoing role of Sonora Quest Laboratories, an Arizona-based joint venture between Banner Health and Quest Diagnostics. Such items help readers understand how Quest Diagnostics partners with health systems to deliver regional laboratory services and hospital lab management solutions.
In addition, Quest Diagnostics reports on developments in specialized diagnostics through subsidiaries and collaborations. News has featured Haystack MRD, a minimal residual disease test developed by Haystack Oncology, a wholly owned subsidiary of Quest Diagnostics, including data presentations at scientific meetings and clinical research collaborations. Other coverage has described a strategic collaboration with Octave Bioscience to expand access to the Octave Multiple Sclerosis Disease Activity Test through Quest’s specimen-collection network.
Visitors to the DGX news page can review these types of updates to follow financial communications, strategic partnerships, scientific data presentations and corporate announcements that shape Quest Diagnostics’ activities in the medical laboratories sector.
Quest Diagnostics made significant environmental progress in 2023 through multiple sustainability initiatives. The company purchased over 40 million kilowatt hours of renewable electricity and installed electric vehicle charging stations in Marlborough, Tampa, and Atlanta. Their fleet optimization reduced driving by 2.6 million miles, saving 96,000 gallons of gasoline and 845 metric tons of CO2 emissions.
The company implemented waste reduction programs at major California laboratories, diverting over 3,500 tons of medical and municipal waste from landfills, generating 1 million kilowatt-hours of electricity, and avoiding 6,900 tons of CO2-equivalent emissions. Their box optimization project achieved an 11% reduction in shipping boxes, saving 23 tons of cardboard.
Quest also obtained ISO 14001 certifications for facilities in Cleveland HeartLab and Chantilly, joining their San Juan Capistrano lab. The company established an Environmental Health Impact Committee to address climate change's health impacts and inform related policies.
Quest Diagnostics has detailed its comprehensive approach to protecting patient data privacy and cybersecurity. The company maintains a robust privacy program with detailed policies, procedures, and annual HIPAA training for all employees. Their cybersecurity framework, overseen by the Chief Information Security Officer, includes multiple security measures aligned with industry best practices.
The company's cybersecurity program encompasses various domains including IT risk management, access controls, data protection, threat intelligence, and incident response. Quest has established an IT Risk Council for oversight and prioritizes supply chain security by assessing vendor security postures. The program adheres to multiple security frameworks including NIST 800, MITRE 40 ATT&CK, and ISO standards, with oversight from the Board of Directors through specialized committees.
Quest Diagnostics (NYSE: DGX) announced that Chairman, CEO and President Jim Davis will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference in Miami. The presentation, scheduled for December 4, 2024, at 3:00 p.m. Eastern Time, will cover the company's strategy, performance, and current market trends.
The session will be webcast live and accessible through Quest's investor relations page at ir.QuestDiagnostics.com. An archived version will be available within 24 hours after the event and remain accessible until January 3, 2025.
Quest Diagnostics (NYSE: DGX) has launched a new Health Coaching service on questhealth.com through Pack Health®. The service connects individuals with board-certified health advisers for personalized support in areas including general health, weight management, chronic kidney disease, type 2 diabetes, and high cholesterol. The program offers two packages: a 4-session package for $225 and a 6-session package for $275, including one-on-one virtual coaching sessions, regular communication, a welcome kit, and digital content. Customers can integrate their Quest lab results with coaching for a more tailored experience.
Parker Family Health Center (PFHC) in Red Bank, NJ, celebrated its facility expansion with a ribbon-cutting ceremony attended by Quest Diagnostics executives. The renovation includes new exam rooms, conference spaces, private patient areas, and a dedicated phlebotomy room for telehealth services. Quest Diagnostics provides no-cost lab testing through its Quest for Health Equity (Q4HE) initiative.
PFHC has operated for over 23 years, recording nearly 190,000 patient visits, and serves uninsured or underinsured Monmouth County residents. The center maintained operations during its 18-month renovation project and is supported by over 130 volunteers including doctors, nurses, interpreters, and administrative staff.
Quest Diagnostics (NYSE: DGX) announced that its Board of Directors has declared a quarterly cash dividend of $0.75 per share. The dividend will be payable on January 29, 2025 to shareholders of record as of January 14, 2025. This announcement demonstrates the company's continued commitment to returning value to shareholders through regular dividend payments.
A former corrections worker shares her journey joining Quest Diagnostics as a logistics driver between Longview, Texas and Shreveport, Louisiana. The employee highlights the independence of her role, the importance of logistics in patient care, and the supportive work environment at Quest. She appreciates the professional atmosphere, knowledge sharing among experienced colleagues, and the opportunity to coordinate social activities between hubs.
Quest Diagnostics through its philanthropic initiative Quest for Health Equity partnered with Choose Healthy Life to address health disparities in Black and brown communities. The collaboration emerged following observations of disproportionate COVID-19 impact on underserved populations. Quest provided COVID-19 testing support and funding to help bridge healthcare gaps. Rev. Kimberly L. Williams, Choose Healthy Life's executive director, highlighted that pre-existing conditions contributed to higher mortality rates in these communities.
Quest Diagnostics highlights the career progression of Jessie Hutchens Maxwell, who evolved from a manual sample processor to a Bio-Analytical Instrument Technician over nearly 7 years. Starting as a temp at Oxford Immunotec before Quest's acquisition, Jessie advanced to the project team, helping develop automated processing systems. In her current role, she maintains and troubleshoots essential automated equipment. The journey showcases Quest's support for employee growth through tuition reimbursement and leadership encouragement, emphasizing the company's commitment to continuous improvement and employee development.
Martha Baer shares her 31-year journey with Quest Diagnostics, starting in 1993 as a courier at Nichols Institute. Through various company transitions and acquisitions, including Corning Clinical Laboratories and Smith Kline Beecham Clinical Laboratories, she experienced significant professional growth. The acquisition of Smith Kline Beecham marked a major expansion, moving operations to a larger facility in Kansas City, MO. Baer progressed from courier to stock clerk, Group Lead, and eventually to her current role as Network Planner and Route Optimization Specialist for the Greater Midwest Region. Her career particularly advanced during the LabOne acquisition in Lenexa, KS, where she took on increased responsibilities.